Patient and caregiver outcomes with levodopa-carbidopa intestinal gel in advanced Parkinson’s disease
Abstract Levodopa-carbidopa intestinal gel (LCIG) has shown to be efficacious in motor and non-motor symptoms (NMS). Nevertheless, studies with patient Quality of Life (QoL) as a primary endpoint are scarce. To assess the effect of LCIG on Advanced Parkinson’s Disease (APD) patients QoL. Secondarily...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | article |
| Language: | EN |
| Published: |
Nature Portfolio
2021
|
| Subjects: | |
| Online Access: | https://doaj.org/article/b29e73979abe4d5b826cdca39dd2e61d |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|